Efficacy of anti-PD-1/PD-L1 antibody after discontinuation of antibody due to non-progressive disease in NSCLC Patients

被引：0
|
作者：
Inoue, Takako [1 ]
Tachihara, Motoko [2 ]
Tamiya, Motohiro [1 ]
Akazawa, Yuki [3 ]
Uenami, Ken [3 ]
Urata, Yoshiko [4 ]
Hattori, Yoshihiro [4 ]
Okuda, Chiyuki [5 ]
Katakami, Nobuyuki [5 ]
Negoro, Shunichi [6 ]
机构：
[1] Osaka Med Canc Inst, Osaka, Japan
[2] Kobe Univ, Grad Sch Med, Dept Resp Med, Kobe, Hyogo, Japan
[3] Natl Hosp Org Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[4] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[5] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
[6] Hyogo Canc Ctr, Akashi, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2-6-1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Discontinuation of Anti-PD-1/PD-L1 Antibody Therapy in the Absence of Disease Progression: Clinical Outcomes in Advanced NSCLC
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Rizzi, M.
    Kuzminin, A.
    Recondo, G., Jr.
    Faura, M.
    Naveira, M.
    Perfetti, A.
    Cerini, M.
    Lupinacci, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S741 - S742
  • [2] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [3] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
  • [4] HYPERPROGRESSIVE DISEASE IN A NSCLC PATIENT AFTER ANTI-PD-L1 ANTIBODY THERAPY DESPITE TO GOOD RESPONSE OF ANTI-PD-1 ANTIBODY WITH TEMPORARY INTERRUPTION DUE TO IRAE
    Shirakawa, C.
    Matsumoto, H.
    Kataoka, Y.
    CHEST, 2020, 157 (06) : 260A - 260A
  • [5] Operability changes in patients with NSCLC after neoadjuvant chemotherapy and anti-PD-1/PD-L1
    Garitaonaindia, Yago
    Baena Espinar, Javier
    Aguado, Carlos
    Cruz, Patricia
    Lopez Castro, Rafael
    Rubio, Jaime
    Gomez, Ana
    Lopez Martin, Ana
    Traseira, Cristina
    Mielgo Rubio, Xabier
    Losada, Beatriz
    Rogado Revuelta, Jacobo
    Romano, Irene
    Luis Campo-Canaveral, Jose
    Gomez de Antonio, David
    Falagan, Sandra
    Rubio, Gustavo
    Javier Montoro, Francisco
    Sereno, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
    Huang, Guanghong
    Sun, Xin
    Liu, Dapeng
    Zhang, Yunfeng
    Zhang, Boxiang
    Xiao, Guodong
    Li, Xiang
    Gao, Xiao
    Hu, Chenhao
    Wang, Meng
    Ren, Hong
    Qin, Sida
    ONCOTARGET, 2018, 9 (03) : 4239 - 4248
  • [7] Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
    Wang, Y.
    Wo, Y.
    Xue, X.
    Xue, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S333 - S333
  • [8] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
    Ken Masuda
    Hidehito Horinouchi
    Midori Tanaka
    Ryoko Higashiyama
    Yuki Shinno
    Jun Sato
    Yuji Matsumoto
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
  • [9] Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
    Tachihara, Motoko
    Negoro, Shunichi
    Inoue, Takako
    Tamiya, Motohiro
    Akazawa, Yuki
    Uenami, Takeshi
    Urata, Yoshiko
    Hattori, Yoshihiro
    Hata, Akito
    Katakami, Nobuyuki
    Yokota, Soichiro
    BMC CANCER, 2018, 18
  • [10] Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
    Motoko Tachihara
    Shunichi Negoro
    Takako Inoue
    Motohiro Tamiya
    Yuki Akazawa
    Takeshi Uenami
    Yoshiko Urata
    Yoshihiro Hattori
    Akito Hata
    Nobuyuki Katakami
    Soichiro Yokota
    BMC Cancer, 18
12345